Article info
PDFRecommendation
EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases
- Correspondence to Professor John D Isaacs, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne NE1 7RU, UK; john.isaacs{at}newcastle.ac.uk
Citation
EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases
Publication history
- Received January 24, 2022
- Accepted April 6, 2022
- First published May 12, 2022.
Online issue publication
March 31, 2023
Article Versions
- Previous version (3 January 2023).
- Previous version (3 January 2023).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.